Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, May 25, 2023
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
Wednesday, May 24, 2023
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
Saturday, May 20, 2023
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
Tuesday, May 16, 2023
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
Monday, May 8, 2023
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
Thursday, April 6, 2023
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
Tuesday, April 4, 2023
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
Monday, April 3, 2023
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
Friday, March 31, 2023
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: